2,257 results on '"Thomas, M."'
Search Results
2. Atypical hemolytic uremic syndrome in the era of terminal complement inhibition: an observational cohort study
3. How I treat cardiovascular complications in patients with lymphoid malignancies
4. Real-world impact of differences in the WHO and ICC classifications of non-Hodgkin lymphoma: a LEO cohort study analysis
5. Neutrophil extracellular traps promote fibrous vascular occlusions in chronic thrombosis
6. Impact of concurrent indolent lymphoma on the clinical outcome of newly diagnosed diffuse large B-cell lymphoma
7. Molecular Classification of Relapsed DLBCL Reveals Novel Biologic Subgroups
8. DEK Regulates B-Cell Proliferative Capacity and Is Associated with Aggressive Disease in Low-Grade B-Cell Lymphoma
9. Atypical hemolytic uremic syndrome in the era of terminal complement inhibition: an observational cohort study
10. Predictive value of staging PET/CT to detect bone marrow involvement and early outcomes in marginal zone lymphoma
11. A simplified scoring system in de novo follicular lymphoma treated initially with immunochemotherapy
12. A CD200R-CD28 fusion protein appropriates an inhibitory signal to enhance T-cell function and therapy of murine leukemia
13. GATA-3 expression identifies a high-risk subset of PTCL, NOS with distinct molecular and clinical features
14. Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL
15. Predictive value of staging PET/CT to detect bone marrow involvement and early outcomes in marginal zone lymphoma
16. Large B-cell transformation in nodular lymphocyte-predominant Hodgkin lymphoma: 40-year experience from a single institution
17. Clinical Outcomes in Patients with Mantle Cell Lymphoma Who Received Autologous Stem Cell Transplant in the Second Line Setting
18. Integrative Genomics Identifies a High-Risk Metabolic and TME Depleted Signature That Predicts Early Clinical Failure in DLBCL
19. Comparison of Treatment-Emergent Adverse Events of Covalent BTK Inhibitors in Clinical Trials in B-Cell Malignancies: A Systematic Review and Meta-Analysis
20. Outcomes and Prognostic Factors of Transformed Follicular Lymphoma: An Analysis from the LEO Consortium
21. Molecular Landscape of Primary Refractory DLBCL
22. Treatment Patterns and Outcomes in Relapsed/Refractory Mantle Cell Lymphoma
23. Development of a Conditional Event-Free Survival Tool in Diffuse Large B-Cell Lymphoma
24. Waldenstrom Macroglobulinemia and the Clinical Implications of Acquired Von Willebrand Syndrome
25. A Genome-Wide Association Study (GWAS) of Event-Free Survival (EFS) in Follicular Lymphoma Patients Treated with Front-Line Immunochemotherapy: A Lysa, Iowa/Mayo MER, and FIL Study
26. Incidence of Second Primary Malignancies in Lymphoma Survivors: A Prospective Cohort Study in the Modern Treatment Era
27. Biological Features of a High-Risk Transcriptional Molecular Subtype in Diffuse Large B-Cell Lymphoma
28. How I treat cardiovascular complications in patients with lymphoid malignancies
29. A genome-wide meta-analysis of nodular sclerosing Hodgkin lymphoma identifies risk loci at 6p21.32
30. Activated granulocytes and inflammatory cytokine signaling drive T-cell lymphoma progression and disease symptoms
31. The mTORC1 inhibitor everolimus has antitumor activity in vitro and produces tumor responses in patients with relapsed T-cell lymphoma
32. BCL2 mutations are associated with increased risk of transformation and shortened survival in follicular lymphoma
33. Activated granulocytes and inflammatory cytokine signaling drive T-cell lymphoma progression and disease symptoms
34. Dose Intensity and Reasons for Dose Alterations in Patients Excluded from Frontline Diffuse Large B-Cell Lymphoma Clinical Trials Based on Eligibility Criteria: A Mayo Clinic Cohort Study
35. Integrative Genomics Identifies a High-Risk Metabolic and TME Depleted Signature That Predicts Early Clinical Failure in DLBCL
36. Predictive Value of Staging PET/CT to Detect Bone Marrow Involvement in Marginal Zone Lymphoma (MZL): An Analysis from LEO MZL Working Group
37. Biological Features of a High-Risk Transcriptional Molecular Subtype in Diffuse Large B-Cell Lymphoma
38. Comparison of Treatment-Emergent Adverse Events of Covalent BTK Inhibitors in Clinical Trials in B-Cell Malignancies: A Systematic Review and Meta-Analysis
39. A Genome-Wide Association Study (GWAS) of Event-Free Survival (EFS) in Follicular Lymphoma Patients Treated with Front-Line Immunochemotherapy: A Lysa, Iowa/Mayo MER, and FIL Study
40. Clinical Outcomes in Patients with Mantle Cell Lymphoma Who Received Autologous Stem Cell Transplant in the Second Line Setting
41. Prediction of Early Disease Progression at 24 Months (POD24) Using Pre-Treatment Biopsies from Patients with Follicular Lymphoma (FL) Treated with Immunochemotherapy (IC)
42. Treatment Patterns and Outcomes in Relapsed/Refractory Mantle Cell Lymphoma
43. Waldenstrom Macroglobulinemia and the Clinical Implications of Acquired Von Willebrand Syndrome
44. Incidence of Second Primary Malignancies in Lymphoma Survivors: A Prospective Cohort Study in the Modern Treatment Era
45. Comparison of Chronic Health Conditions and Health Behaviors in Long-Term Young Adult Hodgkin Lymphoma (YAHL) Survivors to That of Their Unaffected Co-Twin Controls
46. Molecular Landscape of Primary Refractory DLBCL
47. Outcomes and Prognostic Factors of Transformed Follicular Lymphoma: An Analysis from the LEO Consortium
48. FLIPI24: An Improved International Prognostic Model Developed on Early Events in Follicular Lymphoma
49. ALK-negative anaplastic large cell lymphoma is a genetically heterogeneous disease with widely disparate clinical outcomes
50. Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.